These methods can all identify patients that benefit from 2 years of tamoxifen with equal performance, indicating that GEX data might be used to guide adjuvant tamoxifen therapy.
Keyphrases
- breast cancer cells
- end stage renal disease
- estrogen receptor
- positive breast cancer
- ejection fraction
- newly diagnosed
- chronic kidney disease
- early stage
- prognostic factors
- peritoneal dialysis
- postmenopausal women
- electronic health record
- binding protein
- stem cells
- machine learning
- mesenchymal stem cells
- bone marrow
- protein protein
- deep learning
- patient reported